Online inquiry

IVTScrip™ mRNA-Anti-TNFSF11, AMG162(Cap 1, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ2766MR)

This product GTTS-WQ2766MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets TNFSF11 gene. The antibody can be applied in Multiple myeloma (MM), Osteoporosis research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_003701.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 8600
UniProt ID O14788
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFSF11, AMG162(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ2766MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2512MR IVTScrip™ mRNA-Anti-CALCRL, AMG 334(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AMG 334
GTTS-WQ11452MR IVTScrip™ mRNA-Anti-NT5E, MEDI-9447(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MEDI-9447
GTTS-WQ4731MR IVTScrip™ mRNA-Anti-IL21, BOS161721(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA BOS161721
GTTS-WQ6632MR IVTScrip™ mRNA-Anti-CD79B, DCDS0780A(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA DCDS0780A
GTTS-WQ3661MR IVTScrip™ mRNA-Anti-F11, BAY 1213790(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BAY 1213790
GTTS-WQ3487MR IVTScrip™ mRNA-Anti-pcrV, BA1126(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BA1126
GTTS-WQ4647MR IVTScrip™ mRNA-Anti-FGFR1, BMS-986036(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BMS-986036
GTTS-WQ12342MR IVTScrip™ mRNA-Anti-TIGIT, MTIG-7192-A(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA MTIG-7192-A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW